review · Research and Practice in Thrombosis and Haemostasis

Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review

Guy Young
Mariam Safavi
Steven W. Pipe
Francis Nissen
Johannes Oldenburg
Tuende Czirok
Gili Kenet
Johnny Mahlangu

202424 citationsOpen accessUniversity of the Witwatersrand

Abstract

This scoping review consolidates the global published experience for emicizumab in people with hemophilia A and supports the fact that emicizumab has an acceptable safety profile, is effective and efficacious in bleed prevention, and is associated with improvements in QoL.

Research topics

Hemophilia Treatment and Research
Platelet Disorders and Treatments

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1016/j.rpth.2024.102415

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.